Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

375 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Same-day initiation of bictegravir/emtricitabine/tenofovir alafenamide: Week 48 results of the FAST study-IMEA 055.
Bachelard A, Isernia V, Charpentier C, Benalycherif A, Mora M, Donadille C, Duvivier C, Lacombe K, El Mouhebb M, Spire B, Landman R, Descamps D, Peytavin G, Assoumou L, Ghosn J; FAST study group. Bachelard A, et al. Among authors: lacombe k. J Antimicrob Chemother. 2023 Mar 2;78(3):769-778. doi: 10.1093/jac/dkad008. J Antimicrob Chemother. 2023. PMID: 36659824
Four-days-a-week antiretroviral maintenance therapy in virologically controlled HIV-1-infected adults: the ANRS 162-4D trial.
de Truchis P, Assoumou L, Landman R, Mathez D, Le Dû D, Bellet J, Amat K, Katlama C, Gras G, Bouchaud O, Duracinsky M, Abe E, Alvarez JC, Izopet J, Saillard J, Melchior JC, Leibowitch J, Costagliola D, Girard PM, Perronne C; ANRS 162-4D Study Group. de Truchis P, et al. J Antimicrob Chemother. 2018 Mar 1;73(3):738-747. doi: 10.1093/jac/dkx434. J Antimicrob Chemother. 2018. PMID: 29186458 Clinical Trial.
APOBEC-Induced Mutations at Initiation of Cabotegravir + Rilpivirine for Two Patients Infected by HIV-1 Subtype CRF02: The Interest of Systematic Genotyping.
Wembulua BS, Valin N, Lambert-Niclot S, Nerozzi-Banfi E, Chiarabini T, Meynard JL, Lacombe K. Wembulua BS, et al. Among authors: lacombe k. J Acquir Immune Defic Syndr. 2023 Mar 1;92(3):e17-e18. doi: 10.1097/QAI.0000000000003148. J Acquir Immune Defic Syndr. 2023. PMID: 36729654 No abstract available.
Immunomodulators for immunocompromised patients hospitalized for COVID-19: a meta-analysis of randomized controlled trials.
Siempos II, Kalil AC, Belhadi D, Veiga VC, Cavalcanti AB, Branch-Elliman W, Papoutsi E, Gkirgkiris K, Xixi NA, Kotanidou A, Hermine O, Porcher R, Mariette X; CORIMUNO-19 Collaborative Group; DisCoVeRy Study Group; ACTT-2 Study Group; ACTT-3 Study Group. Siempos II, et al. EClinicalMedicine. 2024 Feb 9;69:102472. doi: 10.1016/j.eclinm.2024.102472. eCollection 2024 Mar. EClinicalMedicine. 2024. PMID: 38361992 Free PMC article.
The French national prospective cohort of patients co-infected with HIV and HCV (ANRS CO13 HEPAVIH): early findings, 2006-2010.
Loko MA, Salmon D, Carrieri P, Winnock M, Mora M, Merchadou L, Gillet S, Pambrun E, Delaune J, Valantin MA, Poizot-Martin I, Neau D, Bonnard P, Rosenthal E, Barange K, Morlat P, Lacombe K, Gervais A, Rouges F, See AB, Lascoux-Combe C, Vittecoq D, Goujard C, Duvivier C, Spire B, Izopet J, Sogni P, Serfaty L, Benhamou Y, Bani-Sadr F, Dabis F; ANRS CO 13 HEPAVIH Study Group. Loko MA, et al. Among authors: lacombe k. BMC Infect Dis. 2010 Oct 22;10:303. doi: 10.1186/1471-2334-10-303. BMC Infect Dis. 2010. PMID: 20969743 Free PMC article.
Convalescent Plasma Therapy in Immunocompromised Patients Infected With the BA.1 or BA.2 Omicron SARS-CoV-2.
Richier Q, De Valence B, Chopin D, Gras E, Levi LI, Abi Aad Y, Pacanowski J, Meynard JL, Plaçais L, Fey D, Couture P, Martin-Blondel G, Pestre V, Woessner J, Ancellin S, Weyrich P, Carpentier B, Idri S, Tiberghien P, Surgers L, Hueso T, Lacombe K. Richier Q, et al. Among authors: lacombe k. Influenza Other Respir Viruses. 2024 Mar;18(3):e13272. doi: 10.1111/irv.13272. Influenza Other Respir Viruses. 2024. PMID: 38501337 Free PMC article.
Feasibility, safety, efficacy and potential scaling-up of sofosbuvir-based HCV treatment in Central and West Africa: (TAC ANRS 12311 trial).
Lacombe K, Moh R, Chazallon C, Lemoine M, Sylla B, Fadiga F, Le Carrou J, Marcellin F, Kouanfack C, Ciaffi L, Sartre MT, Sida MB, Diallo A, Gozlan J, Seydi M, Cissé V, Danel C, Girard PM, Toni TD, Minga A, Boyer S, Carrieri P, Attia A; TAC ANRS12311 Study Group. Lacombe K, et al. Sci Rep. 2024 May 3;14(1):10244. doi: 10.1038/s41598-024-57013-1. Sci Rep. 2024. PMID: 38702350 Free PMC article. Clinical Trial.
Salvage Therapy Including Foscarnet and Ibalizumab for Multidrug-Resistant Human Immunodeficiency Virus Type 2 Infection.
Bachelard A, Le Hingrat Q, Ferré VM, Lê M, Peytavin G, Damond F, Charpentier C, Fremont Goudot G, Goupil de Bouille J, Lariven S, Delobel P, Yazdanpanah Y, Descamps D, Matheron S, Ghosn J; ANRS CO05 VIH-2 cohort study group. Bachelard A, et al. Clin Infect Dis. 2024 Apr 10;78(4):1005-1010. doi: 10.1093/cid/ciad695. Clin Infect Dis. 2024. PMID: 38630945
Immunovirological status in people with perinatal and adult-acquired HIV-1 infection: a multi-cohort analysis from France.
Seng R, Frange P, Faye A, Dollfus C, le Chenadec J, Boufassa F, Essat A, Goetghebuer T, Arezes E, Avettand-Fènoël V, Bigna JJ, Blanche S, Goujard C, Meyer L, Warszawski J, Viard JP; ANRS EPF; COVERTE; PRIMO; SEROPRI; COPANA study groups. Seng R, et al. Lancet Reg Health Eur. 2024 Apr 1;40:100885. doi: 10.1016/j.lanepe.2024.100885. eCollection 2024 May. Lancet Reg Health Eur. 2024. PMID: 38576825 Free PMC article.
375 results